JNJ 56914845
Alternative Names: 2336805; GSK-2336805; GSK805; JNJ-56914845Latest Information Update: 02 Aug 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer Janssen
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 07 Aug 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Germany, Belgium, USA (PO)
- 07 Aug 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Germany, France, Bulgaria, Belgium, Puerto Rico, USA (PO)
- 19 Aug 2015 Phase-II development is ongoing in Belgium, Bulgaria, France, Germany, Puerto Rico and USA